Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.

Active

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD). ClinicalTrials.gov record last updated 2026-08-04: active not recruiting. Enrollment is actual at 10 participants. Primary completion is estimated at 2029-01-18. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

Setting

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Registry

NCT06358430

Started

2024-12-02

Enrolled

10 enrolled

Notes

ClinicalTrials.gov record last updated 2026-08-04: active not recruiting. Enrollment is actual at 10 participants. Primary completion is estimated at 2029-01-18. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

Connected

targets

TROP2

drugs

ApprovedMonoclonal antibody (anti-EGFR)

Cetuximab · Erbitux

Phase 1CAR-NK cell therapy

TROP2 CAR/IL-15 cord-blood NK cells

Evidence strength14/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1+4
10 enrolled+5
No structured primary endpoint0
Result: active0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Targets

TROP2

Products

Sourced, not expert-reviewedEvery fact here carries a dated source and the automated checks run on every build. Next scheduled re-check 3 February 2027. No named reviewer has signed it off. It is queued for expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT06358430

A source that has moved or gone is reported by the weekly link check. /audit/

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.

Active

Setting

Phase

Phase 1

Sponsor

M.D. Anderson Cancer Center

Registry

NCT06358430

Started

2024-12-02

Enrolled

10 enrolled

Notes

ClinicalTrials.gov record last updated 2026-08-04: active not recruiting. Enrollment is actual at 10 participants. Primary completion is estimated at 2029-01-18. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

Connected

targets

TROP2

drugs

ApprovedMonoclonal antibody (anti-EGFR)

Cetuximab · Erbitux

Phase 1CAR-NK cell therapy

TROP2 CAR/IL-15 cord-blood NK cells

Evidence strength14/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1+4
10 enrolled+5
No structured primary endpoint0
Result: active0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

Follow this page

Follow by feed

Improve the information

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an edit

Targets

TROP2

Products

Model panel commentary is coming to this page: machine commentary, not clinical review.

Sources

Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.

ClinicalTrials.gov · 1

ClinicalTrials.gov NCT06358430

A source that has moved or gone is reported by the weekly link check. /audit/

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Notes

Connected

Similar pages

targets

drugs

Sources

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Notes

Connected

Similar pages

targets

drugs

Sources

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Overview

Notes

Connected

Similar pages

targets

drugs

Sources

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Overview

Notes

Connected

Similar pages

targets

drugs

Sources